Drug Trial Radar · NCT06990880
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
85
Planned (sponsor's estimate)
Start
Jun 12, 2025
Primary completion
Oct 26, 2027
Study completion Aug 9, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
Conditions
- Neoplasms, Prostate
Interventions
GSK5458514Drug
GSK5458514 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities (DLTs) during DLT observation periodTime frame: Up to 28 days
- Number of participants with adverse events (AEs), serious adverse events (SAEs), by SeverityTime frame: Up to approximately 29 months
- Number of participants with AEs leading to dose modificationsTime frame: Up to approximately 29 months
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Phoenix, Arizona · Recruiting
GSK Investigational Site
Denver, Colorado · Recruiting
GSK Investigational Site
New Haven, Connecticut · Recruiting
GSK Investigational Site
Rochester, Minnesota · Recruiting
GSK Investigational Site
East Brunswick, New Jersey · Recruiting
GSK Investigational Site
Nashville, Tennessee · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Lyon, France · Recruiting
GSK Investigational Site
Villejuif, France · Recruiting
GSK Investigational Site
Kanagawa, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Badajoz, Spain · Recruiting
GSK Investigational Site
Barcelona, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Málaga, Spain · Recruiting
GSK Investigational Site
Pozuelo de AlarcOn Madr, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.